Double blind trial in the treatment of herpes simplex and herpes zoster with adenine arabinoside and idoxuridine.
In a double blind trial adenine arabinoside (Vidarabine) and Idoxuridine (IDU) were tested in herpes simplex and herpes zoster infections. Adenine arabinoside covered 19 patients with HSV and 6 with HZ while IDU 19 with HSV and 6 with HZ. From the statistical analysis it was found that Vidarabine acts shorter than IDU in HSV P less than 0.01, while in HZ no significant difference P less than 0.5 was found, possibly due to the small number of patients tested.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006561:Herpes Simplex / Q000188:drug therapy*; D006562:Herpes Zoster / Q000188:drug therapy*; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D014740:Vidarabine / Q000627:therapeutic use*
D014740:Vidarabine; D007065:Idoxuridine